Biohaven Pharmaceutical (NYSE: BHVN)
Biohaven Pharmaceutical Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Biohaven Pharmaceutical Company Info
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.
News & Analysis
Why Biohaven Stock Is Skyrocketing Today
Promising clinical trial data led investors to bid the stock up, adding to its solid year-to-date gain.
Why Biohaven Stock Caught Fire This Week
Investors are excited about the company's recent progress.
Why Biohaven Stock Skyrocketed Again Today
The "new" Biohaven is enjoying plenty of attention from investors.
Why Biohaven Stock Is Soaring Today
The "old" Biohaven is gone, leaving the "new" Biohaven to rise.
Why Biohaven Pharmaceutical Stock Soared Today
An industry titan wants to buy the biotech for a whopping $11.6 billion.
Will This Biopharma Company Continue to Crush It?
Migraine sufferers certainly hope so.
Here's Why Biohaven Pharmaceutical Is Soaring Today
Preliminary sales figures for the company's new migraine drug were much better than expected.
Why Biohaven Pharmaceutical Stock Is Tanking Today
Alzheimer's claims another drug candidate.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.